Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
EHAB Stock Forecast 2026-2027
$13.72
Current Price
$702.82M
Market Cap
Buy 0
Hold 6
Sell 0
Wall St Analyst Ratings
Distance to EHAB Price Targets
+0.6%
To High Target of $13.80
+0.6%
To Median Target of $13.80
+0.6%
To Low Target of $13.80
EHAB Price Momentum
-1.9%
1 Week Change
+0.7%
1 Month Change
+78.6%
1 Year Change
+48.8%
Year-to-Date Change
-3.5%
From 52W High of $14.22
+112.1%
From 52W Low of $6.47
📊 TOP ANALYST CALLS
Did EHAB Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Enhabit is one of their latest high-conviction picks.
Latest EHAB Stock Price Targets & Analyst Predictions
Based on our analysis of 13 Wall Street analysts, EHAB has a neutral consensus with a median price target of $13.80 (ranging from $13.80 to $13.80). The overall analyst rating is Buy (6.0/10). Currently trading at $13.72, the median forecast implies a 0.6% upside. This outlook is supported by 0 Buy, 6 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Ryan Langston at TD Cowen, projecting a 0.6% upside. Conversely, the most conservative target is provided by Ryan Langston at TD Cowen, suggesting a 0.6% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
EHAB Analyst Ratings
0
Buy
6
Hold
0
Sell
EHAB Price Target Range
Low
$13.80
Average
$13.80
High
$13.80
Current: $13.72
Latest EHAB Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for EHAB.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 6, 2026 | TD Cowen | Ryan Langston | Hold | Downgrade | $13.80 |
| Feb 24, 2026 | UBS | A.J. Rice | Neutral | Downgrade | $13.80 |
| Feb 23, 2026 | Jefferies | Brian Tanquilut | Hold | Downgrade | $13.80 |
| Feb 23, 2026 | Leerink Partners | Whit Mayo | Market Perform | Maintains | $13.80 |
| Jan 22, 2026 | Oppenheimer | Michael Wiederhorn | Outperform | Upgrade | $14.00 |
| Jan 13, 2026 | TD Cowen | Ryan Langston | Buy | Upgrade | $12.00 |
| Jan 8, 2026 | UBS | A.J. Rice | Buy | Upgrade | $12.00 |
| Aug 8, 2025 | UBS | A.J. Rice | Neutral | Maintains | $8.50 |
| Dec 9, 2024 | Jefferies | Brian Tanquilut | Buy | Upgrade | $9.50 |
| Nov 19, 2024 | Leerink Partners | Market Perform | Reiterates | $N/A | |
| Jun 27, 2024 | B of A Securities | Joanna Gajuk | Underperform | Maintains | $8.00 |
| May 14, 2024 | Leerink Partners | Whit Mayo | Market Perform | Upgrade | $8.50 |
| May 9, 2024 | Jefferies | Brian Tanquilut | Hold | Downgrade | $8.75 |
| Mar 11, 2024 | TD Cowen | Ryan Langston | Market Perform | Maintains | $11.00 |
| Mar 7, 2024 | Oppenheimer | Michael Wiederhorn | Perform | Maintains | $N/A |
| Mar 7, 2024 | UBS | A.J. Rice | Neutral | Upgrade | $9.50 |
| Mar 6, 2024 | Jefferies | Brian Tanquilut | Buy | Maintains | $14.00 |
| Dec 12, 2023 | TD Cowen | Ryan Langston | Market Perform | Initiates | $12.00 |
| Aug 11, 2023 | Credit Suisse | Jonathan Yong | Neutral | Maintains | $12.00 |
| Jul 17, 2023 | Goldman Sachs | Jamie Perse | Neutral | Maintains | $13.00 |
Enhabit Inc. (EHAB) Competitors
The following stocks are similar to Enhabit based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Enhabit Inc. (EHAB) Financial Data
Valuation Metrics
Market Cap
$702.82M
Enterprise Value
$1.18B
P/E Ratio
N/A
PEG Ratio
22.1x
Price/Sales
0.7x
Growth & Margins
Revenue Growth (YoY)
+4.7%
Gross Margin
+48.7%
Operating Margin
+5.3%
Net Margin
-0.4%
EPS Growth
+4.7%
Financial Health
Cash/Price Ratio
+6.3%
Current Ratio
1.6x
Debt/Equity
88.6x
ROE
-0.5%
ROA
+3.3%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Enhabit Inc. (EHAB) Business Model
About Enhabit Inc.
What They Do
Provides home health and hospice care services.
Business Model
Enhabit Inc. operates by offering high-quality, patient-centered home health and hospice services. The company generates revenue through reimbursement from Medicare and private insurance for the care provided to patients, particularly those transitioning from hospital to home settings.
Additional Information
With a commitment to innovation and stringent care standards, Enhabit Inc. aims to reduce hospital readmissions and improve patient outcomes. Their services are increasingly important as the population ages and the demand for personalized, in-home care solutions rises.
Company Information
Sector
Healthcare
Industry
Medical Care Facilities
Employees
10,800
CEO
Ms. Barbara Ann Jacobsmeyer B.S., M.A., P.T.
Country
United States
IPO Year
2022
Website
www.ehab.comEnhabit Inc. (EHAB) Latest News & Analysis
Latest News
Enhabit Sets Stockholder Meeting Date of May 12, 2026, to Approve Transaction with Kinderhook
3 days ago
Quick Summary
Enhabit, Inc. will hold a special stockholders' meeting on May 12, 2026, to vote on a merger agreement with Anchor Parent, LLC.
Why It Matters
The upcoming vote on the merger could significantly impact Enhabit’s stock value and future operations, influencing investor sentiment and potential returns.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
The CBOE Volatility Index (VIX) is at 25.50, up 34.9% in a month, prompting investors to seek stable, income-generating stocks with low market correlation.
Why It Matters
A rising VIX indicates heightened market volatility, prompting investors to seek stable, income-generating assets, which can impact stock selection and market trends.
Source: 24/7 Wall Street
Market Sentiment:
Positive
Quick Summary
Kaskela Law LLC is investigating the fairness of Enhabit, Inc.'s proposed buyout at $13.80 per share by Kinderhook Industries, amid concerns it may undervalue the company.
Why It Matters
The investigation into Enhabit’s buyout price may signal potential undervaluation, impacting shareholder sentiment and stock price volatility as the deal progresses.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Enhabit, Inc. (NYSE: EHAB) reported its Q4 2025 results, highlighting year-over-year increases in patient census, revenue, and Adjusted EBITDA, signaling its growth and strategic execution.
Why It Matters
Enhabit’s strong fourth-quarter performance signals growth in patient numbers and revenue, indicating a positive trend that could enhance investor confidence and stock value.
Source: Business Wire
Market Sentiment:
Neutral
Enhabit (EHAB) Matches Q4 Earnings Estimates
1 month ago
Quick Summary
Enhabit (EHAB) reported Q3 earnings of $0.14 per share, matching estimates, and up from $0.04 per share year-over-year.
Why It Matters
Enhabit's earnings match expectations and show significant year-over-year growth, indicating improved financial performance and stability, which can positively influence investor confidence.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Enhabit (EHAB) qualifies as a strong momentum stock at a reasonable price, making it a potential investment opportunity for value-focused investors.
Why It Matters
Enhabit’s strong momentum and reasonable pricing signal potential growth, attracting investors seeking value in trending stocks, which may lead to increased demand and price appreciation.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About EHAB Stock
What is Enhabit Inc.'s (EHAB) stock forecast for 2026?
Based on our analysis of 13 Wall Street analysts, Enhabit Inc. (EHAB) has a median price target of $13.80. The highest price target is $13.80 and the lowest is $13.80.
Is EHAB stock a good investment in 2026?
According to current analyst ratings, EHAB has 0 Buy ratings, 6 Hold ratings, and 0 Sell ratings. The stock is currently trading at $13.72. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for EHAB stock?
Wall Street analysts predict EHAB stock could reach $13.80 in the next 12 months. This represents a 0.6% increase from the current price of $13.72. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Enhabit Inc.'s business model?
Enhabit Inc. operates by offering high-quality, patient-centered home health and hospice services. The company generates revenue through reimbursement from Medicare and private insurance for the care provided to patients, particularly those transitioning from hospital to home settings.
What is the highest forecasted price for EHAB Enhabit Inc.?
The highest price target for EHAB is $13.80 from Ryan Langston at TD Cowen, which represents a 0.6% increase from the current price of $13.72.
What is the lowest forecasted price for EHAB Enhabit Inc.?
The lowest price target for EHAB is $13.80 from Ryan Langston at TD Cowen, which represents a 0.6% increase from the current price of $13.72.
What is the overall EHAB consensus from analysts for Enhabit Inc.?
The overall analyst consensus for EHAB is neutral. Out of 13 Wall Street analysts, 0 rate it as Buy, 6 as Hold, and 0 as Sell, with a median price target of $13.80.
How accurate are EHAB stock price projections?
Stock price projections, including those for Enhabit Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 19, 2026 4:00 PM UTC